MX2017013884A - Compuestos de pirazolo- y triazolo-pirimidina antivirales contra virus sincitial respiratorio (vsr). - Google Patents

Compuestos de pirazolo- y triazolo-pirimidina antivirales contra virus sincitial respiratorio (vsr).

Info

Publication number
MX2017013884A
MX2017013884A MX2017013884A MX2017013884A MX2017013884A MX 2017013884 A MX2017013884 A MX 2017013884A MX 2017013884 A MX2017013884 A MX 2017013884A MX 2017013884 A MX2017013884 A MX 2017013884A MX 2017013884 A MX2017013884 A MX 2017013884A
Authority
MX
Mexico
Prior art keywords
triazolo
pyrazolo
pyrimidine compounds
compounds
rsv antiviral
Prior art date
Application number
MX2017013884A
Other languages
English (en)
Other versions
MX369040B (es
Inventor
Anil Koul
Pierre Jean-Marie Bernard Raboisson
Jérôme Émile Georges Guillemont
Benjamin MICHAUT Antoine
Francis Alain Lançois David
André Emmy Roymans Dirk
Rogovoy Boris
Bichko Vadim
Yvonne Raymonde Lardeau Delphine
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MX2017013884A publication Critical patent/MX2017013884A/es
Publication of MX369040B publication Critical patent/MX369040B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de pirazolo- y triazolo-pirimidina sustituidos novedosos de fórmula (I) que tienen actividad antiviral, en particular, que tienen una actividad inhibidora sobre la replicación del virus sincitial respiratorio (VSR); la invención se refiere además a composiciones farmacéuticas que comprenden estos compuestos y a los compuestos para su uso en el tratamiento de la infección por el virus sincitial respiratorio. (ver Fórmula).
MX2017013884A 2015-04-28 2016-04-27 Compuestos de pirazolo- y triazolo-pirimidina antivirales contra virus sincitial respiratorio (vsr). MX369040B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153753P 2015-04-28 2015-04-28
US201562204390P 2015-08-12 2015-08-12
PCT/EP2016/059392 WO2016174079A1 (en) 2015-04-28 2016-04-27 Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds

Publications (2)

Publication Number Publication Date
MX2017013884A true MX2017013884A (es) 2018-03-16
MX369040B MX369040B (es) 2019-10-25

Family

ID=55860847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013884A MX369040B (es) 2015-04-28 2016-04-27 Compuestos de pirazolo- y triazolo-pirimidina antivirales contra virus sincitial respiratorio (vsr).

Country Status (29)

Country Link
US (3) US10208048B2 (es)
EP (1) EP3288942B1 (es)
JP (1) JP6698693B2 (es)
KR (1) KR102538565B1 (es)
CN (1) CN107531715B (es)
AU (1) AU2016254700B2 (es)
BR (1) BR112017023263B1 (es)
CA (1) CA2981404C (es)
CL (1) CL2017002709A1 (es)
CY (1) CY1125329T1 (es)
DK (1) DK3288942T3 (es)
EA (1) EA035689B1 (es)
ES (1) ES2905550T3 (es)
HR (1) HRP20211728T1 (es)
HU (1) HUE057626T2 (es)
IL (1) IL254750B (es)
JO (1) JO3637B1 (es)
LT (1) LT3288942T (es)
MA (1) MA41974A (es)
MX (1) MX369040B (es)
PH (1) PH12017501958B1 (es)
PL (1) PL3288942T3 (es)
PT (1) PT3288942T (es)
SG (1) SG11201708786SA (es)
SI (1) SI3288942T1 (es)
TW (1) TWI703146B (es)
UA (1) UA120448C2 (es)
WO (1) WO2016174079A1 (es)
ZA (1) ZA201707320B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) * 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
AU2019216260B2 (en) * 2018-01-31 2023-03-02 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
CA3095277A1 (en) * 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against rsv
US12016863B2 (en) 2018-05-03 2024-06-25 Georgia State University Research Foundation, Inc. Inhibitors of RSV replication and applications thereof
EA202191482A1 (ru) 2018-11-26 2021-12-14 Янссен Сайенсиз Айрлэнд Анлимитед Компани Другие гетероароматические соединения, обладающие активностью против rsv
CA3124783A1 (en) 2018-12-27 2020-07-02 Taisho Pharmaceutical Co., Ltd. Pyrazolo[1,5-a]pyrimidine macrocyclic compound
JP2022533429A (ja) 2019-05-23 2022-07-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｒｓｖに対する活性を有する他のヘテロ芳香族化合物
CN111440173B (zh) * 2020-03-27 2021-05-14 山东大学 一种pi3k抑制剂的制备方法
WO2022020889A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Method of treatment of cytomegalovirus
WO2022020891A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Methods of prophylaxis and treatment of corona virus
CN121021491A (zh) 2020-10-28 2025-11-28 盐野义制药株式会社 具有抗病毒活性的酰胺衍生物
MX2023009294A (es) 2021-02-08 2023-11-09 Univ Columbia Analogos inspirados por oxa-ibogaina para el tratamiento de trastornos neurologicos y psiquiatricos.
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
US20260015337A1 (en) * 2022-06-17 2026-01-15 Trawsfynydd Therapeutics, Inc. Compounds for treatment a coronavirus infection
WO2024121263A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121261A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121262A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121264A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508535A (ja) 1994-12-22 1999-07-27 バイオケム ファーマ インコーポレイテッド 低分子量２環式トロンビン阻害剤
JP2000501063A (ja) 1995-06-29 2000-02-02 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤の組み合わせ
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972966A (en) 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
WO2001005768A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Tricyclic compounds bearing acyloxymethoxycarbonyl pendants
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AU2002332659A1 (en) 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
CA2499523C (en) 2002-09-20 2011-04-19 Medisyn Technologies, Inc. Therapeutic agents and corresponding treatments
CA2497333A1 (en) 2002-09-26 2004-04-08 Pfizer Inc. Pyrazole derivatives as reverse transcriptase inhibitors
AU2003275632A1 (en) 2002-10-25 2004-05-13 Mitsubishi Pharma Corporation N-oxide compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US7323567B2 (en) 2003-10-30 2008-01-29 Boehringer Ingelheim (Canada) Ltd. RSV polymerase inhibitors
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
RU2422444C2 (ru) 2003-12-24 2011-06-27 Байота Сайентифик Менеджмент Пти Лтд Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
MX2007016537A (es) * 2005-06-20 2008-03-06 Tibotec Pharm Ltd 1,3-dihidro-benzoimidazol-onas 1-(2-amino-3-(alquilo sustituido)-3h-bencimidazolilmetil)-3-sustituidas con actividad sobre virus respiratorios sinciciales.
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP1957476A1 (en) 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
CA2658764A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20120121540A1 (en) 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
US20100063047A1 (en) 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
EP2350068B1 (en) 2008-10-23 2017-08-30 Boehringer Ingelheim International GmbH Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2010104306A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
MX2012015292A (es) * 2010-06-24 2013-05-30 Gilead Sciences Inc Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
WO2012100342A1 (en) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
KR102181318B1 (ko) * 2012-04-17 2020-11-20 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 화합물 및 방법
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
CN107001377B (zh) 2014-12-08 2019-09-10 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5-a]嘧啶衍生物
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Also Published As

Publication number Publication date
HK1248230A1 (zh) 2018-10-12
US20180105529A1 (en) 2018-04-19
IL254750A0 (en) 2017-11-30
ZA201707320B (en) 2020-08-26
US10208048B2 (en) 2019-02-19
JO3637B1 (ar) 2020-08-27
KR102538565B1 (ko) 2023-05-30
BR112017023263A2 (pt) 2018-08-07
EP3288942A1 (en) 2018-03-07
WO2016174079A1 (en) 2016-11-03
LT3288942T (lt) 2021-12-10
PT3288942T (pt) 2021-12-17
MX369040B (es) 2019-10-25
PL3288942T3 (pl) 2022-02-21
JP2018514544A (ja) 2018-06-07
US10611769B2 (en) 2020-04-07
AU2016254700A1 (en) 2017-10-19
EA035689B1 (ru) 2020-07-27
CA2981404A1 (en) 2016-11-03
PH12017501958A1 (en) 2018-03-26
CL2017002709A1 (es) 2018-04-20
TW201708227A (zh) 2017-03-01
CY1125329T1 (el) 2024-02-16
DK3288942T3 (da) 2022-01-17
CN107531715B (zh) 2021-03-30
BR112017023263B1 (pt) 2023-04-11
AU2016254700B2 (en) 2020-01-02
HUE057626T2 (hu) 2022-05-28
EP3288942B1 (en) 2021-10-27
SI3288942T1 (sl) 2022-01-31
US11084826B2 (en) 2021-08-10
ES2905550T3 (es) 2022-04-11
US20190248793A1 (en) 2019-08-15
IL254750B (en) 2020-07-30
TWI703146B (zh) 2020-09-01
UA120448C2 (uk) 2019-12-10
US20200223855A1 (en) 2020-07-16
MA41974A (fr) 2018-03-07
KR20170139122A (ko) 2017-12-18
EA201792370A1 (ru) 2018-02-28
SG11201708786SA (en) 2017-11-29
PH12017501958B1 (en) 2018-03-26
JP6698693B2 (ja) 2020-05-27
CA2981404C (en) 2023-09-19
HRP20211728T1 (hr) 2022-02-18
CN107531715A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
PH12017501958B1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
MX368162B (es) Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
PH12017501534A1 (en) Antiviral compounds
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12015500355B1 (en) Compounds for the treatment of paramoxyvirus viral infections
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
MX2021002168A (es) Compuestos antivirales.
MX381994B (es) Inhibidor de janus quinasa.
PH12018501962B1 (en) Stablizied soluble pre-fusion rsv f proteins
MX369798B (es) Derivados macrociclicos de pirimidina.
MX383213B (es) Inhibidores de tirosina-cinasas
MX2017014035A (es) Formas solidas novedosas.
PH12020550673A1 (en) Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv)
PH12017500558A1 (en) 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
MX2021014301A (es) Otros compuestos heteroaromaticos que tienen actividad contra el vrs.
MX2020011200A (es) Compuestos heteroaromaticos que tienen actividad contra vrs.
MX2020008061A (es) Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs.
MX2021006138A (es) Otros compuestos heteroaromaticos que tienen actividad contra el vrs.
MX368323B (es) Derivados tricíclicos de pirazolo [1,5-a]pirimidina sustituidos con piperidina con actividad inhibidora en la replicación del virus sincitial respiratorio (vsr).
AU2014298561A8 (en) Substituted pyridine-piperazinyl analogues as RSV antiviral compounds
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
WO2016072854A3 (en) Pantothenamide analogues
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.

Legal Events

Date Code Title Description
FG Grant or registration